Acurx Pharmaceuticals Regains Nasdaq Listing

Strategic Insights -

Acurx Pharmaceuticals, Inc. has confirmed that it has regained compliance with the minimum bid price and stockholders' equity threshold under Nasdaq Listing Rules, ensuring the continuation of its listing on the Nasdaq Stock Market. This achievement comes on the heels of the company's successful development of a new class of antibiotics for difficult-to-treat bacterial infections. As a late-stage biopharmaceutical company, Acurx is dedicated to bringing innovative treatments to patients suffering from antibiotic-resistant infections.

Key Takeaways:

  • Acurx Pharmaceuticals, Inc. has regained compliance with the minimum bid price and stockholders' equity threshold under Nasdaq Listing Rules.
  • The company's approach to developing antibiotic candidates involves a Gram-positive selective spectrum (GPSS) that targets the bacterial enzyme DNA polymerase IIIC, inhibiting DNA replication and leading to bacterial cell death.
  • Acurx's R&D pipeline includes antibiotic product candidates for Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP), and B. anthracis (anthrax).
  • The Company's lead product candidate, ibezapolstat, is Phase 3 ready and plans to begin international clinical trials next year, subject to obtaining financing.
  • Acurx's preclinical pipeline includes development of an oral product candidate for treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI), with plans to treat inhaled anthrax in parallel.

Statistics:

  • The minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) is $1.00.
  • The minimum stockholders' equity threshold under Listing Rule 5550(b)(1) is $2.5 million.
  • Acurx spends approximately $5 million to $6 million per month on operations and people.

Sources:

  • Acurx Pharmaceuticals, Inc. (press release, September 3, 2025)
  • Acurx Pharmaceuticals, Inc. (press release, December 31, 2024, Form 10-K, SEC filing)